The flare-up checklist is a tool to help patients identify if they might have had an exacerbation in the past 12 months, or if their symptoms might be worsening.
On completion, patients are encouraged to discuss their results with their healthcare professional for further guidance.
Click here to revisit the GOLD definitions of Mild, Moderate and Severe COPD exacerbations.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
We are living in unprecedented times. The COVID-19 outbreak will have a lasting impact on the way we live and how we think about our health, for generations to come.
AstraZeneca stands in solidarity with the global respiratory community, both in the fight against COVID-19 and in ensuring patients get the accurate information they need to effectively manage their condition during this period.
Please find information below that directs you to the current clinical guidance on managing respiratory conditions, and information on COVID-19 and the potential impact for people living with chronic respiratory diseases.
Global Initiative for Chronic Obstructive Lung Disease - GOLD COVID19 Guidance
World Health Organization (WHO) - Information about the coronavirus
European Respiratory Society (ERS) - COVID-19 resource centre
A COPD exacerbation is defined as a short-term worsening of COPD symptoms that requires additional therapy1
These can be classified as:
Mild: treated with short-acting bronchodilators (SABDs) only1
Moderate: treated with SABDs plus antibiotics and / or oral corticosteroids1
Severe: requires hospitalisation or emergency room visit1
A history of exacerbations is the strongest predictor of future exacerbation risk. The risk of re-hospitalisation or death also increases substantially after a first severe COPD exacerbation, and with each subsequent event 9,10
Poor lung function (i.e. FEV1) is associated with a greater risk of exacerbations. Patients with a higher FEV1 (GOLD Stage 1) may lose more lung function following an exacerbation than patients with more severe COPD11
In patients with a history of exacerbations, a higher blood eosinophil count predicts an increased risk of future exacerbations12
Patients with the highest symptom burden (i.e. a SQRQ score ≥60) have a 40% increase in risk of exacerbation and are twice as likely to be admitted to hospital13
Patients with comorbidities such as lung cancer, heart failure, dyspepsia and asthma are at greater risk of experiencing frequent exacerbations14